Radiation Oncology/NSCLC/Recurrent
|
Front Page: Radiation Oncology | RTOG Trials |
|
|
NSCLC: Main Page | Overview | Anatomy | Screening | Early Stage Operable | Early Stage Inoperable | Locally Advanced Unresectable | Locally Advanced Resectable | Palliation | Brachytherapy | PCI | Miscellaneous | Large cell neuroendocrine | Level I Evidence | |
Non-small cell lung cancer Recurrence
edit- MD Anderson; 2017 PMID 28259750 -- "Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial." (Sun B, J Thorac Oncol. 2017 Jun;12(6):983-992. doi: 10.1016/j.jtho.2017.02.018. Epub 2017 Mar 1.)
- Phase II. 59 patients with isolated NSCLC local recurrence or lung parenchyma metastasis <=3 cm. Prior definitive treatment. Median age 70 years. SABR 50/4. Median F/U 4.8 years
- Outcome: Re-recurrence 32%. 5-year local failure 5%, regional failure 10%, DM 22%. 5-year PFS 41%. 5-year OS 56%
- Toxicity: Grade 3+ 5%; no Grade 4-5 events
- Conlusion: Salvage SABR provides excellent control with minimal toxicity